The government needs to get on with its own recommendations and speed up access to life-changing drugs
As the rest of Europe competes to rehome the European Medicines Agency (EMA) from London, minds at home are finally focusing on what that means for access to new treatments in a post-Brexit Britain.
The warnings have been clear: without an effective relationship with the EMA, there is a risk t…
